Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin liposomal - Thermosome

Next Previous
Drug Profile

Doxorubicin liposomal - Thermosome

Alternative Names: DPPG2-TSL-DOX; THE-001

Latest Information Update: 25 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Thermosome
  • Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Soft tissue sarcoma
  • Preclinical Bladder cancer; Breast cancer

Most Recent Events

  • 17 Oct 2025 Preliminary efficacy, adverse event and pharmacokinetics data from a phase I trial in Soft tissue sarcoma presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)
  • 14 Oct 2025 Phase-I development is ongoing in Germany (https://www.thermosome.com/pipeline/)
  • 28 May 2025 Thermosome completes phase-I clinical trials in Soft tissue sarcoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in Germany (IV) (NCT05858710)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top